Change to Yellow Card reporting in children

The MHRA no longer requires all suspected adverse drug reactions (ADRs) in children and adolescents to be reported.

The quickest ADR reporting method is online but a paper copy of the Yellow Card form can alternatively be posted to the MHRA. | SCIENCE PHOTO LIBRARY
The quickest ADR reporting method is online but a paper copy of the Yellow Card form can alternatively be posted to the MHRA. | SCIENCE PHOTO LIBRARY

This change has been made in response to feedback that mandatory reporting of all suspected ADRs in children was impractical and deterred reporting. The advice for reporting adverse reactions is now the same for adults and children.

When to report

A Yellow Card needs to be completed for any ADR that is:

  • serious or results in harm and/or
  • associated with newer drugs and vaccines identified by the black triangle symbol (▼).

A serious reaction is one that is fatal, life-threatening, disabling or incapacitating, causes a congenital abnormality or results in hospitalisation, or is medically significant for any other reason.

ADRs meeting the above criteria should be reported if they are suspected to be caused by medicines, vaccines, herbal or complementary products, including from misuse or overdose, or from use of unlicensed or off-label medicines.

Where harm occurs as a result of a medication error, a Yellow Card may be completed or the error can be reported via the National Reporting and Learning System.

A paper copy of the Yellow Card form can be found at the back of the print issue of MIMS. This will be updated for the next quarterly edition (December) to reflect the changes to reporting ADRs in children and adolescents.

Further information: MHRA Drug Safety Update, September 2014


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.